Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 8;3(1):e150.
doi: 10.1017/ash.2023.417. eCollection 2023.

Is there an association between peri-diagnostic vaccination and clinical outcomes in COVID-19 patients?

Julia A Casazza #  1 , Bhaskar Thakur #  2   3 , Trish M Perl  4 , John J Hanna  2   4 , Marlon I Diaz  2 , Milan Ho  1 , Heather Lanier  1 , Madison Pickering  2 , Sameh N Saleh  5 , Pankil Shah  6 , Dimpy Shah  7 , Ann Marie Navar  3   4 , Christoph U Lehmann  2   3   8   9 , Richard J Medford #  2   4   10 , Robert W Turer #  2   11
Affiliations

Is there an association between peri-diagnostic vaccination and clinical outcomes in COVID-19 patients?

Julia A Casazza et al. Antimicrob Steward Healthc Epidemiol. .

Abstract

Background: Peri-diagnostic vaccination contemporaneous with SARS-CoV-2 infection might boost antiviral immunity and improve patient outcomes. We investigated, among previously unvaccinated patients, whether vaccination (with the Pfizer, Moderna, or J&J vaccines) during the week before or after a positive COVID-19 test was associated with altered 30-day patient outcomes.

Methods: Using a deidentified longitudinal EHR repository, we selected all previously unvaccinated adults who initially tested positive for SARS-CoV-2 between December 11, 2020 (the date of vaccine emergency use approval) and December 19, 2021. We assessed whether vaccination between days -7 and +7 of a positive test affected outcomes. The primary measure was progression to a more severe disease outcome within 30 days of diagnosis using the following hierarchy: hospitalization, intensive care, or death.

Results: Among 60,031 hospitalized patients, 543 (0.91%) were initially vaccinated at the time of diagnosis and 59,488 (99.09%) remained unvaccinated during the period of interest. Among 316,337 nonhospitalized patients, 2,844 (0.90%) were initially vaccinated and 313,493 (99.1%) remained unvaccinated. In both analyses, individuals receiving vaccines were older, more often located in the northeast, more commonly insured by Medicare, and more burdened by comorbidities. Among previously unvaccinated patients, there was no association between receiving an initial vaccine dose between days -7 and +7 of diagnosis and progression to more severe disease within 30 days compared to patients who did not receive vaccines.

Conclusions: Immunization during acute SARS-CoV-2 infection does not appear associated with clinical progression during the acute infectious period.

Keywords: COVID-19; acute infection; outcomes; vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1.
Figure 1.
CONSORT diagram illustrating how patients were selected from the OPTUM database for inclusion in the study.
See this image and copyright information in PMC

References

    1. COVID-19 Map – Johns Hopkins Coronavirus Resource Center [Internet]. [cited 2021 Sep 12]. https://coronavirus.jhu.edu/map.html
    1. Siu K-L, Chan C-P, Kok K-H, Woo PC-Y, Jin D-Y. Suppression of innate antiviral response by severe acute respiratory syndrome coronavirus M protein is mediated through the first transmembrane domain. Cell Mol Immunol [Internet] 2014. [cited 2021 Sep 12];11:141. pmc/articles/PMC4003381/ - PMC - PubMed
    1. Hsu JC-C, Laurent-Rolle M, Pawlak JB, Wilen CB, Cresswell P. Translational shutdown and evasion of the innate immune response by SARS-CoV-2 NSP14 protein. Proc Natl Acad Sci [Internet] 2021. [cited 2021 Sep 12];118. https://www.pnas.org/content/118/24/e2101161118 - PMC - PubMed
    1. Nakhlband A, Fakhari A, Azizi H. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies. Naunyn Schmiedebergs Arch Pharmacol [Internet] 2021. [cited 2021 Sep 12];394:1. /pmc/articles/PMC7883756/ - PMC - PubMed
    1. Services H. General recommendations on immunization. J Am Med Assoc 2011;262:339–340.

LinkOut - more resources